Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers
- Conditions
- Sleep Disorders, Circadian Rhythm
- Interventions
- Drug: Placebo
- Registration Number
- NCT02108353
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Brief Summary
EuRhythDia II is a multicenter, randomized, double-blind controlled study. The rationale of EuRhythdia is to explore the effects of 12 weeks of timed melatonin treatment on circadian rhythm, metabolic control and cardiovascular function in night shift workers. The 12 weeks of intervention will be followed by 12 weeks of washing out.
- Detailed Description
Modern lifestyle has dramatically changed the daily rhythms of life. Physical activity, diet and light exposure are no longer restricted to daytime hours due to increased shift work. Recent scientific reports have shown that shift work leads to disruption of circadian rhythms and promotes diabetes, obesity and cardiovascular disease. Until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes and obesity have been conducted in man. Thus, knowledge of the molecular pathways and the responsibles genes in man are missing and have been identified only in animal studies.
The objective of the project is to achieve breakthroughs in the understanding of the causality between inner clock rhythm disturbances and the development of type 2 diabetes and obesity. The provided data on the interaction between genes, epigenetics, metabolism, cardiovascular function and the internal clock are intended to contribute to identify novel biomarkers and novel therapeutic approaches focusing on circadian rhythms to reduce the occurence of diabetes and obesity in shift worker.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
- Male and female above the age of 18
- Night shift workers on regular night shifts (at least 6 months before inclusion into the study and at least 4 night shifts per month during the study period
- pregnancy or breast feeding
- Known autoimmune disease
- Current or relevant history of physical or psychiatric illness
- Evidence of renal insufficiency or liver disease
- Known or suspected intolerance or hypersensitivity to the study medication
- Use of certain drugs within 4 weeks prior to the inclusion to the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Melatonin 2mg Melatonin 2mg The study medication will be compared to placebo control. Placebo Placebo The study medication will be compared to placebo control.
- Primary Outcome Measures
Name Time Method Efficacy (AUC) baseline and 12 weeks The change in the area under the curve (AUC) of blood glucose during an oral glucose tolerance test between baseline and 12 weeks of intervention.
- Secondary Outcome Measures
Name Time Method Efficacy AUC insulin 12 weeks baseline and 12 weeks The change in the area under the curve (AUC) of blood insulin during an oral glucose tolerance test between baseline and 12 weeks of intervention.
Efficacy BMI baseline, 12 weeks and 24 weeks The change in body weight, BMI, abdominal circumference, biomarkers and vascular function between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy expression pattern of clock genes baseline, 12 weeks and 24 weeks The change in the gene expression patterns of Clock genes in peripheral blood monocytic cells (PBMC) between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy glucose homeostasis (QUICKI-index) baseline, 12 weeks and 24 weeks The change in the QUICKI-index (quantitative insulin sensitivity check index) between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy glucose homeostasis (Stumvoll ISI-index) baseline, 12 weeks and 24 weeks The change in HbA1c between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy glucose homeostasis (HbA1c) baseline, 12 weeks and 24 weeks The change in the Stumvoll ISI (Stumvoll insulin sensitivity index) between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy glucose homeostasis (HOMA-index) baseline, 12 weeks and 24 weeks The change in the HOMA-index (Homeostasis Model Assessment) between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy AUC Insulin 24 weeks 12 weeks and 24 weeks The change in the area under the curve (AUC) of blood insulin during an oral glucose tolerance test between week 12 and week 24 (= after 12 weeks without intervention).
Efficacy epigenetic profiles 12 weeks and 24 weeks The differences in epigenetic profiles of genes involved in circadian rhythm between the study groups after 12 weeks of intervention and between week 12 and 24.
Efficacy biomarkers baseline, 12 weeks and 24 weeks The differences in plasma and serum biomarkers between baseline and 12 weeks of intervention and between week 12 and 24.
Efficacy AUC glucose 24 weeks 12 weeks and 24 weeks The change in the area under the curve (AUC) of blood glucose during an oral glucose tolerance test between week 12 and week 24 (= after 12 weeks without intervention).
Trial Locations
- Locations (3)
CTC North GmbH & Co. KG
🇩🇪Hamburg, Germany
Department of Systems Medicine
🇮🇹Rome, Lazio, Italy
University Medical Center Aachen
🇩🇪Aachen, North Rhine-Westphalia, Germany